Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Abpro Holdings ( (ABP) ) is now available.
On December 15, 2025, Abpro Holdings, Inc. announced the submission of an investigational new drug (IND) application to the U.S. FDA for ABP-102/CT-P72, a HER2 × CD3 T cell engager for HER2-positive cancers. This submission, a collaboration with Celltrion, Inc., marks a significant milestone as it is Abpro’s first IND submission for a phase 1 trial in a solid tumor indication. The trial, expected to begin in the first half of 2026, will evaluate the safety and efficacy of ABP-102/CT-P72, which has shown promising preclinical results. This development underscores Abpro’s progress in its immuno-oncology pipeline and its potential impact on patients with limited treatment options.
The most recent analyst rating on (ABP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Abpro Holdings stock, see the ABP Stock Forecast page.
More about Abpro Holdings
Abpro Holdings, Inc. is a biotechnology company based in Burlington, Massachusetts, focusing on developing novel breakthrough therapeutics for solid tumors. The company is advancing a pipeline of next-generation antibody therapies for HER2-positive cancers, non-HER2-positive gastric and liver cancer, and conditions like wet age-related macular degeneration and diabetic macular edema using its proprietary DiversImmune® platform.
Average Trading Volume: 158,123
Technical Sentiment Signal: Sell
Current Market Cap: $15.94M
For a thorough assessment of ABP stock, go to TipRanks’ Stock Analysis page.